|
|
Minda Industries has redeemed commercial paper aggregating Rs 25 crore on 05 December 2020.
|
|
|
Aarey Drugs & Pharmaceuticals announced that the 30th Annual General Meeting (AGM) of the company will be held on 28 December 2020.
|
|
|
Orchid Pharma announced that the 27th Annual General Meeting (AGM) of the company will be held on 30 December 2020.
|
|
|
Riddhi Corporate Services announced that the 10th Annual General Meeting (AGM) of the company will be held on 28 December 2020.
|
|
|
Venmax Drugs & Pharmaceuticals announced that the 31st Annual General Meeting (AGM) of the company will be held on 28 December 2020.
|
|
|
Tata Consultancy Services announced that it has helped Extreme Networks to successfully adopt a flexible consumption-as-a-service subscription model, enabling the roll-out of its ExtremeCloud™ IQ cloud management platform, strengthening its customer relationships and helping the cloud-driven networking leader gain market share.
TCS was chosen as a strategic partner by Extreme Networks in their digital transformation journey to
unlock the power of the subscription-based economy by spearheading this business-critical initiative
from conceptualization and design to solution implementation. The transformation required changes
in processes and underlying systems across the customer engagement lifecycle, including offer
creation to marketing, sales, fulfillment, and renewals. In addition to these changes, new capabilities
like subscription billing, and new business performance metrics were also introduced.
Adding a subscription-based model has enabled Extreme Networks to become more customer centric,
elevating them as a true partner in their customers' cloud journeys. By understanding consumption
patterns and making recommendations through deep customer insights, Extreme Networks can build
lasting customer relationships resulting in significant revenue growth.
|
|
|
Zydus announced that it has received permission to initiate the Phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate.
NLRP3 inflammasomes are involved in the inflammation process by production and release of proinflammatory cytokines IL-1â and IL-18. This harmful inflammation within the body leads to the
onset and development of various kinds of diseases, including Acute Respiratory Distress Syndrome
(ARDS), auto-immune diseases, inflammatory diseases, cardiovascular diseases, metabolic disorders,
Gastro-intestinal diseases (inflammatory bowel disease), renal diseases and CNS diseases.
Speaking on the development, Pankaj R. Patel, Chairman, Cadila Healthcare Ltd., said, “We will
study the safety, tolerability, pharmacokinetics and pharmacodynamics of ZYIL1 in this Phase I
clinical trial in healthy human volunteers. We are committed to developing these pioneering novel
treatments to the clinic for the patients in need.”
|
|
|
ICICI Bank has allotted 408,159 equity shares of face value
of 2 each on 07 December 2020 under the Employee Stock Option Scheme (ESOS).
|
|
|
Hindalco Industries announced plans to set up a 34,000-tonne extrusion plant at Silvassa. The new plant will service the fast-growing market for extruded aluminium products in the western and southern regions.
The Rs 730-crore project in Silvassa signals a big step forward in Hindalco's downstream
strategy as the Company revives its long-term downstream investment plan. The Company's
intent is to build a larger value-added product portfolio over the next few years. This
investment indicates confidence in the economic revival, which in turn will grow the demand
for downstream value-added products.
|
|
|
Ganesh Benzoplast announced that the 33rd Annual General Meeting (AGM) of the company will be held on 29 December 2020.
|